Effect of CTLA-4 Inhibition on Inflammation and Apoptosis After Spinal Cord Injury
This study aimed to investigate the influence of CTLA-4 on SCI. A weight-drop technique was used to establish a rat model of SCI. To examine the safeguarding effect of CTLA-4 on the restoration of motor function in rats with SCI, the Basso-Beattie-Bresnahan (BBB) scale and inclined plane test were employed to assess locomotion. Neuronal degeneration and apoptosis were assessed using terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling (TUNEL) and Fluoro-Jade B labeling, respectively, and the activity of microglial cells was examined by immunofluorescence. To evaluate the impact of CTLA4 on SCI, the levels...
Source: Cell Research - February 17, 2024 Category: Cytology Authors: Wei Mao Feng Jiang Chunping Zhu Jun Liu Zhao Lu Yinwei Qian Jinchun Xiao Source Type: research
Effect of CTLA-4 Inhibition on Inflammation and Apoptosis After Spinal Cord Injury
This study aimed to investigate the influence of CTLA-4 on SCI. A weight-drop technique was used to establish a rat model of SCI. To examine the safeguarding effect of CTLA-4 on the restoration of motor function in rats with SCI, the Basso-Beattie-Bresnahan (BBB) scale and inclined plane test were employed to assess locomotion. Neuronal degeneration and apoptosis were assessed using terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling (TUNEL) and Fluoro-Jade B labeling, respectively, and the activity of microglial cells was examined by immunofluorescence. To evaluate the impact of CTLA4 on SCI, the levels...
Source: Neurochemical Research - February 17, 2024 Category: Neuroscience Authors: Wei Mao Feng Jiang Chunping Zhu Jun Liu Zhao Lu Yinwei Qian Jinchun Xiao Source Type: research
GSE232512 Development of a 6-gene mesothelioma-specific prognostic signature using whole transcriptomic analysis of mouse and human tumors
Contributors : Scott A Fisher ; Kiarash BehrouzfarSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusBackground: Mesothelioma is an aggressive, fatal cancer that is inextricably linked to asbestos exposure. Recent trials using a combination of the immune checkpoint inhibitors ipilimumab and nivolumab has significantly improved treatment outcomes, however durable treatment responses remain restricted to a subset of patients (15-20%), highlighting the need to identify strategies that better predict treatment response.Method: Here, we performed RNAseq on a large tumor biobank from genetica...
Source: GEO: Gene Expression Omnibus - February 15, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research
Case report: A rare case of immunotherapy induced isolated left CN VI palsy in a patient with unresectable melanoma
ConclusionThis is the first reported UK case of immunotherapy-induced isolated cranial nerve VI palsy. Multiple irAEs are more common with combination immunotherapy and its occurrence is associated with more favourable outcomes in melanoma. Immunotherapy continues to revolutionise oncological care, but clinicians must be cognizant of unpredictable irAEs, which may require prompt assessment and intervention. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - February 12, 2024 Category: Cancer & Oncology Source Type: research
Discussion to: Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non –small cell lung cancer
Presenter: Dr Hope Feldman (Source: The Journal of Thoracic and Cardiovascular Surgery)
Source: The Journal of Thoracic and Cardiovascular Surgery - February 10, 2024 Category: Cardiovascular & Thoracic Surgery Tags: Thoracic Source Type: research
Neoadjuvant Immunotherapy With Ipilimumab Plus Nivolumab in Mismatch Repair Deficient/Microsatellite Instability-High Colorectal Cancer: A Preliminary Report of Case Series
CONCLUSION: Neoadjuvant immunotherapy with ipilimumab plus nivolumab induced tumor regression with a major clinical and pathological response in advanced dMMR/MSI-H CRC. Notably, patients do not achieve a complete response to neoadjuvant immunotherapy, additional neoadjuvant immunotherapy may offer benefits. Further research is needed to assess the long-term efficacy of this strategy.PMID:38336555 | DOI:10.1016/j.clcc.2024.01.002 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 9, 2024 Category: Cancer & Oncology Authors: Tao Pan Hui Yang Wu-Yi Wang Yuan-Yi Rui Zi-Jian Deng Yung-Chang Chen Chao Liu Hai Hu Source Type: research
Efficacy and toxicity of immune checkpoint inhibitors combination therapy for advanced renal cell carcinoma: a systematic review and network meta-analysis
ConclusionPembrolizumab plus lenvatinib and pembrolizumab plus axitinib resulted in the highest PFS and OS rates, respectively. Pembrolizumab plus axitinib may be the best option when AEs are a concern.Systematic review registrationhttps://inplasy.com/, identifier INPLASY202410078. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - February 8, 2024 Category: Allergy & Immunology Source Type: research
The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns
Ann Dermatol Venereol. 2024 Feb 6;151(1):103243. doi: 10.1016/j.annder.2023.103243. Online ahead of print.NO ABSTRACTPMID:38325268 | DOI:10.1016/j.annder.2023.103243 (Source: Annales de Dermatologie et de Cenereologie)
Source: Annales de Dermatologie et de Cenereologie - February 7, 2024 Category: Dermatology Authors: M Amini-Adle J-P Arnault F Aubin N Beneton G Bens F Brunet-Possenti P C élerier J Charles L Crumbach S Dalac S Darras J De Quatrebarbes M Dinulescu C Dutriaux C Gaudy E G érard D Giacchero F Granel-Brocard F Grange T Jouary N Kramkimel C Lebb é Y Le Co Source Type: research
Recent advances and remaining challenges in lung cancer therapy
Chin Med J (Engl). 2024 Feb 7. doi: 10.1097/CM9.0000000000002991. Online ahead of print.ABSTRACTLung cancer remains the most common cause of cancer death. Given the continued research into new drugs and combination therapies, outcomes in lung cancer have been improved, and clinical benefits have been expanded to a broader patient population. However, the overall cure and survival rates for lung cancer patients remain low, especially in metastatic cases. Among the available lung cancer treatment options, such as surgery, radiation therapy, chemotherapy, targeted therapies, and alternative therapies, immunotherapy has shown ...
Source: Chinese Medical Journal - February 7, 2024 Category: General Medicine Authors: Tasha Barr Shoubao Ma Zhixin Li Jianhua Yu Source Type: research
The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns
Ann Dermatol Venereol. 2024 Feb 6;151(1):103243. doi: 10.1016/j.annder.2023.103243. Online ahead of print.NO ABSTRACTPMID:38325268 | DOI:10.1016/j.annder.2023.103243 (Source: Annales de Dermatologie et de Venereologie)
Source: Annales de Dermatologie et de Venereologie - February 7, 2024 Category: Dermatology Authors: M Amini-Adle J-P Arnault F Aubin N Beneton G Bens F Brunet-Possenti P C élerier J Charles L Crumbach S Dalac S Darras J De Quatrebarbes M Dinulescu C Dutriaux C Gaudy E G érard D Giacchero F Granel-Brocard F Grange T Jouary N Kramkimel C Lebb é Y Le Co Source Type: research
The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns
Ann Dermatol Venereol. 2024 Feb 6;151(1):103243. doi: 10.1016/j.annder.2023.103243. Online ahead of print.NO ABSTRACTPMID:38325268 | DOI:10.1016/j.annder.2023.103243 (Source: Annales de Dermatologie et de Cenereologie)
Source: Annales de Dermatologie et de Cenereologie - February 7, 2024 Category: Dermatology Authors: M Amini-Adle J-P Arnault F Aubin N Beneton G Bens F Brunet-Possenti P C élerier J Charles L Crumbach S Dalac S Darras J De Quatrebarbes M Dinulescu C Dutriaux C Gaudy E G érard D Giacchero F Granel-Brocard F Grange T Jouary N Kramkimel C Lebb é Y Le Co Source Type: research
Recent advances and remaining challenges in lung cancer therapy
Chin Med J (Engl). 2024 Feb 7. doi: 10.1097/CM9.0000000000002991. Online ahead of print.ABSTRACTLung cancer remains the most common cause of cancer death. Given the continued research into new drugs and combination therapies, outcomes in lung cancer have been improved, and clinical benefits have been expanded to a broader patient population. However, the overall cure and survival rates for lung cancer patients remain low, especially in metastatic cases. Among the available lung cancer treatment options, such as surgery, radiation therapy, chemotherapy, targeted therapies, and alternative therapies, immunotherapy has shown ...
Source: Chinese Medical Journal - February 7, 2024 Category: General Medicine Authors: Tasha Barr Shoubao Ma Zhixin Li Jianhua Yu Source Type: research
The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns
Ann Dermatol Venereol. 2024 Feb 6;151(1):103243. doi: 10.1016/j.annder.2023.103243. Online ahead of print.NO ABSTRACTPMID:38325268 | DOI:10.1016/j.annder.2023.103243 (Source: Annales de Dermatologie et de Venereologie)
Source: Annales de Dermatologie et de Venereologie - February 7, 2024 Category: Dermatology Authors: M Amini-Adle J-P Arnault F Aubin N Beneton G Bens F Brunet-Possenti P C élerier J Charles L Crumbach S Dalac S Darras J De Quatrebarbes M Dinulescu C Dutriaux C Gaudy E G érard D Giacchero F Granel-Brocard F Grange T Jouary N Kramkimel C Lebb é Y Le Co Source Type: research
The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns
Ann Dermatol Venereol. 2024 Feb 6;151(1):103243. doi: 10.1016/j.annder.2023.103243. Online ahead of print.NO ABSTRACTPMID:38325268 | DOI:10.1016/j.annder.2023.103243 (Source: Annales de Dermatologie et de Cenereologie)
Source: Annales de Dermatologie et de Cenereologie - February 7, 2024 Category: Dermatology Authors: M Amini-Adle J-P Arnault F Aubin N Beneton G Bens F Brunet-Possenti P C élerier J Charles L Crumbach S Dalac S Darras J De Quatrebarbes M Dinulescu C Dutriaux C Gaudy E G érard D Giacchero F Granel-Brocard F Grange T Jouary N Kramkimel C Lebb é Y Le Co Source Type: research
Recent advances and remaining challenges in lung cancer therapy
Chin Med J (Engl). 2024 Feb 7. doi: 10.1097/CM9.0000000000002991. Online ahead of print.ABSTRACTLung cancer remains the most common cause of cancer death. Given the continued research into new drugs and combination therapies, outcomes in lung cancer have been improved, and clinical benefits have been expanded to a broader patient population. However, the overall cure and survival rates for lung cancer patients remain low, especially in metastatic cases. Among the available lung cancer treatment options, such as surgery, radiation therapy, chemotherapy, targeted therapies, and alternative therapies, immunotherapy has shown ...
Source: Chinese Medical Journal - February 7, 2024 Category: General Medicine Authors: Tasha Barr Shoubao Ma Zhixin Li Jianhua Yu Source Type: research
